The global Baricitinib Market is experiencing an impressive growth phase. Baricitinib, a powerful small molecule inhibitor originally co-developed by Eli Lilly and Incyte, operates as a selective Janus kinase (JAK) 1 and JAK2 inhibitor. By interrupting intracellular cytokine signaling pathways, the drug prevents the inflammatory cascades responsible for severe tissue damage. https://www.databridgemarketresearch.com/